Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: BK who wrote (5438)	5/31/1998 11:28:00 AM
From: Sergio H	Respond to of 29382

Bruce, we all agree that whenever Jim Strauss mentions a stock that he is buying, it is worth looking into. So I did my research into this stock. I still have unsanswered questions, so I have not made up my mind about BJCT yet, but it is an interesting and timely stock. The sector is just beginning to get hot. Here's an excerpt from Hambrecht and Quist research about the biotechs. I went to their site trying to find if they're the firm that dropped coverage on BJCT and could not find that information: <The Case for Biotech: A Rally ApproachesHealthcare ------------------------------------------------------------------------ April 27, 1998 (16 pp.)Richard A. van den Broek, CFA ÿÿ(212) 207-1412 ÿrbroek@hamquist.comJay H. Kim ÿÿ(212) 207-1461 ÿjaykim@hamquist.comDow 30: ÿ8917.64 S&P 500: ÿ1086.54 ------------------------------------------------------------------------ ÿÿÿ We believe that both external and internal factors are aligned in favor of biotech. First, we view the macroenvironment as positive, with pharmaceutical companies at historically high valuations and Asian economic troubles threatening to undermine profit growth for other industries. The weak performance of the sector over the past few years and the market's focus on large-cap and technology stocks during that time have led to a decline in institutional ownership and a weak financing environment. This lack of investor interest and supply of new stock position the group for an upward move in response to even a modestly positive catalyst. Second, after years in the making, biotechnology is finally beginning to show its strength. A wave of new products is approaching the market, and the sector is well financed by historical standards. This might be a sufficient catalyst to set a rally in motion. ÿÿÿ Biotech is at the early stages of a long-term bull run, driven by a genomics-based technology that is just beginning to engage. We expect that biotechnology will generate a growing number of products for at least the next five to 10 years, creating several new large successful companies in the process. We encourage investors to begin to gain exposure now, in advance of this run. > You brought up the pain factor in the needleless injections and this is what BJCT has to say : <Depending upon the characteristics of the injectate, most people report little to no pain with a Biojector injection.5 Some drug preparations contain components that cause stinging, burning, aching or other painful reactions and this does not change with the Biojector. Bioject recommends that the medication package insert be read carefully so each patient can be advised of a medication's side effect. > bioject.com Timeliness is what makes this stock most attractive. With all of the attention that terrorism is receiving and President Clinton's plans for national detox centers, this stock may be receiving some attention. <<Picture: ILLINOIS STATE DEPARTMENT OF HEALTH SELECTS BIOJECTOR 2000 TO SUPPORT STATEWIDE EMERGENCY NEEDS PROGRAM>ÿ ILLINOIS STATE DEPARTMENT OF HEALTH SELECTS BIOJECTOR 2000 TO SUPPORT STATEWIDE EMERGENCY NEEDS PROGRAM Marks A First in State Government Approach to Crisis Preparedness in Healthcare Represents New Growth Market for Bioject Portland, Oregon - January 12, 1998 - Bioject Medical Technologies Inc. (NASDAQ: BJCT), the leading manufacturer of jet injection devices for needle-free subcutaneous and intramuscular injections, today announced that it has signed an agreement with the Health Department of the State of Illinois. According to the agreement, the Company will provide its Biojectorƒ 2000 needle-free jet injection system as part of a statewide preparedness program for epidemic outbreaks of diseases. The State will also provide the Biojectorƒ systems to local government-sponsored immunization programs on an as-needed basis. Jim O'Shea, Bioject's chairman and chief executive officer, said: "We are honored to be working with the State of Illinois as it demonstrates a new level of government commitment to ensuring public health. Few state health departments have so carefully prepared for such crises in advance. "Participating in this statewide emergency preparedness program is particularly exciting for Bioject because it marks an entry into a new arena of significant growth potential. Equally important, this agreement is a strong complement to the renewed contracts recently made by several existing key customers, including the States of New Mexico, Oklahoma, North Carolina and the City of New York. We intend to fuel this strong momentum by continuing to win new business in both the public and private sectors," concluded O'Shea. Said Mike Redmond, Bioject's vice president of Sales & Marketing: "These agreements reflect continued customer satisfaction with the Biojectorƒ 2000. Furthermore, the Illinois program underscores the critical role the Biojectorƒ 2000 can play in the rapid and efficient management of an epidemic outbreak of disease." Redmond continued, "The Biojector's ability to deliver subcutaneous and intra-muscular injections in doses up to 1.0 cc provides the range of flexibility needed to be prepared for treating a wide variety of diseases. Additionally, studies show that the Biojectorƒ 2000 not only delivers medication more quickly and effectively than other injection devices, but it's easier to use, safer for care givers, and less painful for patients. In fact, as illustrated by its impressive success in the City of Springfield's school immunization programs last year, children clearly prefer the Biojectorƒ 2000 over needle injections.> bioject.com